Arda Therapeutics Secures $43M Series A Financing to Advance Targeted Cell Depletion Therapies
Arda Therapeutics, a pioneer in targeted cell depletion therapies for chronic diseases, today announced the successful completion of a $43 million Series A financing round. The round was led by existing investor Andreessen Horowitz (a16z Bio + Health), with participation from Two Sigma Ventures, RV Invest, Eli Lilly and Company, GV, Biovision Ventures, Valhalla Ventures, Indicator Ventures, Alumni Ventures, LifeLink Ventures, Mana Ventures, Gaingels and ExitFund.Readmore